Comparative healthcare resource utilization and costs of empagliflozin and GLP ‐1 receptor agonists in type 2 diabetes

Documenti analoghi

• Post hoc Population Standardization of Trial Emulation Studies in Claims Data: An RCT ‐ DUPLICATE Analysis
  di: Phyo Than Htoo, et al.
  Pubblicazione: (2026)
• GLP ‐ 1RA and the risk of non‐arteritic anterior ischaemic optic neuropathy in patients with type 2 diabetes: A population‐based study
  di: Helen Tesfaye, et al.
  Pubblicazione: (2025)
• GLP‐1 receptor agonists not associated with increased suicidality
  Pubblicazione: (2024)
• Considerations on peri‐operative management of GLP ‐1 receptor agonists
  di: Glenio B. Mizubuti, et al.
  Pubblicazione: (2024)
• Insulin requirements after switching from GLP ‐1 receptor agonist to dual GIP / GLP ‐1 receptor agonist in patients with type 2 diabetes mellitus
  di: Alexa M. Lahey, et al.
  Pubblicazione: (2025)